Live Breaking News & Updates on Azeria Therapeutics
Stay updated with breaking news from Azeria therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Steve Myatt, the newly-appointed chief executive of Macomics By Kristy Dorsey Macomics, a drug discovery spin-out from the University of Edinburgh, has raised a further £4.2 million in funding and announced three new senior appointments as it progresses its work in the field of tackling cancer tumours. The deal was led by transatlantic scientific investors Epidarex Capital following initial seed funding of £3.2m from Epidarex and the Scottish Investment Bank in the middle of last year. Edinburgh-based investment fund Caribou Property has joined as a new investor in this latest round. Co-founded in 2019 by the university’s Jeffrey Pollard and Luca Cassetta, Macomics is focused on the role of macrophages in increasing the body’s immune defence against tumours. It has R&D and office facilities in Edinburgh and Cambridge. ....
(0) Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology Funds will accelerate macrophage-based therapeutics R&D portfolio and target discovery capability; expansion of facilities in Edinburgh and Cambridge Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has closed a follow-on financing of £4.24 million from its 2020 Seed round, bringing the total amount raised to £7.44m. ....